External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions

被引:13
作者
Lopes, Sandra [1 ]
Johansen, Pierre [1 ]
Lamotte, Mark [2 ]
McEwan, Phil [3 ]
Olivieri, Anamaria-Vera [4 ]
Foos, Volker [3 ]
机构
[1] Novo Nordisk AS, Soborg, Denmark
[2] IQVIA, Zaventem, Belgium
[3] Hlth Econ & Outcomes Res Ltd, Cardiff, Wales
[4] IQVIA, Basel, Switzerland
关键词
BODY-MASS INDEX; LIFETIME HEALTH OUTCOMES; OBSTRUCTIVE SLEEP-APNEA; DIABETES-MELLITUS; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; PRIMARY PREVENTION; GLUCOSE CONTROL; HEART-DISEASE; PRIMARY-CARE;
D O I
10.1007/s40273-020-00941-3
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background For economic models to be considered fit for purpose, it is vital that their outputs can be interpreted with confidence by clinicians, budget holders and other stakeholders. Consequently, thorough validation of models should be carried out to enhance confidence in their predictions. Here, we present results of external dependent and independent validations of the Core Obesity Model (COM), which was developed to assess the cost-effectiveness of weight management interventions. Objective The aim was to assess the external validity of the COM (version 6.1), in line with best practice guidance from the International Society for Pharmacoeconomics and Outcomes Research and the Society for Medical Decision Making. Methods For validation, suitable sources and outcomes were identified, and used to populate the COM with relevant inputs to allow prediction of study outcomes. Study characteristics were entered into the COM to replicate either the studies used to develop the model (dependent validation) or those not included in the model (independent validation). The concordance between predicted and observed outcomes was then assessed using established statistical methods and generation of mean error estimates. Results For most outcomes, the predictions of the COM showed good linear correlation with observed outcomes, as evidenced by the high coefficients of determination (R(2)values). The independent validation revealed a degree of underestimation in predictions of cardiovascular (CV) disease and mortality, and type 2 diabetes. Conclusion The predictions generated by the risk equations used in the COM showed good concordance both with the studies used to develop the model and with studies not included in the model. In particular, the concordance observed in the external dependent validation suggests that the COM accurately predicts obesity-related event rates observed in the studies used to develop the model. However, the impact of existing CV risk, as well as mortality, is a key area for future refinement of the COM. Our results should increase confidence in the estimates derived from the COM and reduce uncertainty associated with analyses using this model.
引用
收藏
页码:1123 / 1133
页数:11
相关论文
共 57 条
[1]   Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study [J].
Anand, S. S. ;
Dagenais, G. R. ;
Mohan, V. ;
Diaz, R. ;
Probstfield, J. ;
Freeman, R. ;
Shaw, J. ;
Lanas, F. ;
Avezum, A. ;
Budaj, A. ;
Jung, H. ;
Desai, D. ;
Bosch, J. ;
Yusuf, S. ;
Gerstein, H. C. .
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2012, 19 (04) :755-764
[2]  
[Anonymous], 2000, World Health Organ Tech Rep Ser, V41, P8
[3]  
[Anonymous], 2017, Health matters: obesity and the food environment
[4]   What is the clinical effectiveness and cost-effectiveness of using drugs in treating obese patients in primary care? A systematic review [J].
Ara, R. ;
Blake, L. ;
Gray, L. ;
Hernandez, M. ;
Crowther, M. ;
Dunkley, A. ;
Warren, F. ;
Jackson, R. ;
Rees, A. ;
Stevenson, M. ;
Abrams, K. ;
Cooper, N. ;
Davies, M. ;
Khunti, K. ;
Sutton, A. .
HEALTH TECHNOLOGY ASSESSMENT, 2012, 16 (05) :1-+
[5]   MODELLING THE COST-EFFECTIVENESS OF ORLISTAT AS A TREATMENT FOR OBESITY IN PRIMARY CARE [J].
Ara, R. ;
Blake, L. .
VALUE IN HEALTH, 2011, 14 (07) :A416-A417
[6]   Effect of the APOE Polymorphism and Age Trajectories of Physiological Variables on Mortality: Application of Genetic Stochastic Process Model of Aging [J].
Arbeev, Konstantin G. ;
Ukraintseva, Svetlana V. ;
Kulminski, Alexander M. ;
Akushevich, Igor ;
Arbeeva, Liubov S. ;
Culminskaya, Irina V. ;
Wu, Deqing ;
Yashin, Anatoliy I. .
SCIENTIFICA, 2012, 2012
[7]   Modeling Good Research Practices-Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1 [J].
Caro, J. Jaime ;
Briggs, Andrew H. ;
Siebert, Uwe ;
Kuntz, Karen M. .
VALUE IN HEALTH, 2012, 15 (06) :796-803
[8]  
Chen Xiaoli, 2014, Int J Soc Sci Stud, V2, P89
[9]   A model to estimate the lifetime health outcomes of patients with Type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68) [J].
Clarke, PM ;
Gray, AM ;
Briggs, A ;
Farmer, AJ ;
Fenn, P ;
Stevens, RJ ;
Matthews, DR ;
Stratton, IM ;
Holman, RR .
DIABETOLOGIA, 2004, 47 (10) :1747-1759
[10]   Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial [J].
Colhoun, HM ;
Betteridge, DJ ;
Durrington, PN ;
Hitman, GA ;
Neil, HAW ;
Livingstone, SJ ;
Thomason, MJ ;
Mackness, MI ;
Charlton-Menys, V ;
Fuller, JH .
LANCET, 2004, 364 (9435) :685-696